TW202208408A - 多特異性蛋白質 - Google Patents
多特異性蛋白質 Download PDFInfo
- Publication number
- TW202208408A TW202208408A TW110117538A TW110117538A TW202208408A TW 202208408 A TW202208408 A TW 202208408A TW 110117538 A TW110117538 A TW 110117538A TW 110117538 A TW110117538 A TW 110117538A TW 202208408 A TW202208408 A TW 202208408A
- Authority
- TW
- Taiwan
- Prior art keywords
- fap
- seq
- protein
- recombinant protein
- binding
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20174847 | 2020-05-14 | ||
| EP20174847.2 | 2020-05-14 | ||
| EP20181498.5 | 2020-06-22 | ||
| EP20181498 | 2020-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202208408A true TW202208408A (zh) | 2022-03-01 |
Family
ID=75904957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110117538A TW202208408A (zh) | 2020-05-14 | 2021-05-14 | 多特異性蛋白質 |
Country Status (13)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| WO2022190016A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| EP4387984A1 (en) * | 2021-08-17 | 2024-06-26 | Athebio AG | Variants of ankyrin repeat domains |
| WO2023110983A1 (en) * | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| WO2025163082A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2026150109A1 (en) * | 2025-01-10 | 2026-07-16 | Molecular Partners Ag | Mesothelin-specific binding constructs and their use in radiotherapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| KR20070085314A (ko) | 2004-11-12 | 2007-08-27 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 재조합 뉴캐슬 질환 바이러스 |
| KR101268939B1 (ko) | 2005-07-08 | 2013-05-30 | 유니버시티 오브 취리히 | 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이 |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2906591A1 (en) | 2012-10-15 | 2015-08-19 | Universität Zürich | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| US9458211B1 (en) | 2015-04-02 | 2016-10-04 | Molecular Partners Ag | Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains |
| MY196882A (en) | 2016-09-22 | 2023-05-08 | Molecular Partners Ag | Recombinant binding proteins and their use |
| CN110402255B (zh) * | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子 |
| AU2018363922B2 (en) | 2017-11-08 | 2025-06-12 | Kyowa Kirin Co., Ltd. | Bispecific antibody which binds to CD40 and EpCAM |
| US11242396B2 (en) * | 2018-10-01 | 2022-02-08 | Hoffmann-La Roche Inc. | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
| KR20220016944A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 개선된 안정성을 갖는 설계된 안키린 반복 도메인 |
| JP2022535564A (ja) | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| CA3139164A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| EP3980452A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| CN114945584A (zh) | 2019-12-11 | 2022-08-26 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| AU2021271131A1 (en) | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
| WO2022101458A1 (en) | 2020-11-16 | 2022-05-19 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted cd40 agonists |
| AU2021403658A1 (en) | 2020-12-16 | 2023-06-29 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| US20240108746A1 (en) | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| TW202300644A (zh) | 2021-02-24 | 2023-01-01 | 中國大陸商杭州啟函生物科技有限公司 | 免疫細胞中的嵌合抗原受體 |
| US20240317852A1 (en) | 2021-03-09 | 2024-09-26 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| KR20230169182A (ko) | 2021-04-09 | 2023-12-15 | 몰리큘라 파트너스 아게 | 신규한 DARPin 기반 CD70 인게이저 |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
-
2021
- 2021-05-14 IL IL298168A patent/IL298168A/en unknown
- 2021-05-14 EP EP21725187.5A patent/EP4149959A1/en active Pending
- 2021-05-14 TW TW110117538A patent/TW202208408A/zh unknown
- 2021-05-14 AU AU2021271129A patent/AU2021271129A1/en active Pending
- 2021-05-14 MX MX2022014326A patent/MX2022014326A/es unknown
- 2021-05-14 JP JP2022568689A patent/JP7843711B2/ja active Active
- 2021-05-14 BR BR112022023049A patent/BR112022023049A2/pt unknown
- 2021-05-14 CA CA3178785A patent/CA3178785A1/en active Pending
- 2021-05-14 US US17/925,144 patent/US20240279290A1/en active Pending
- 2021-05-14 WO PCT/EP2021/062860 patent/WO2021229067A1/en not_active Ceased
- 2021-05-14 US US17/302,898 patent/US12331090B2/en active Active
- 2021-05-14 CN CN202180044299.9A patent/CN115768786A/zh active Pending
- 2021-05-14 KR KR1020227043615A patent/KR20230022176A/ko active Pending
-
2022
- 2022-12-02 CO CONC2022/0017445A patent/CO2022017445A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022017445A2 (es) | 2023-02-16 |
| BR112022023049A2 (pt) | 2022-12-20 |
| MX2022014326A (es) | 2023-02-09 |
| US20210395318A1 (en) | 2021-12-23 |
| CN115768786A (zh) | 2023-03-07 |
| US20240279290A1 (en) | 2024-08-22 |
| IL298168A (en) | 2023-01-01 |
| EP4149959A1 (en) | 2023-03-22 |
| JP7843711B2 (ja) | 2026-04-10 |
| US12331090B2 (en) | 2025-06-17 |
| KR20230022176A (ko) | 2023-02-14 |
| WO2021229067A1 (en) | 2021-11-18 |
| CA3178785A1 (en) | 2021-11-18 |
| JP2023528204A (ja) | 2023-07-04 |
| AU2021271129A9 (en) | 2023-03-02 |
| AU2021271129A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331090B2 (en) | Multispecific proteins | |
| US20240025961A1 (en) | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 | |
| JP7153626B2 (ja) | 抗ヒト4-1bb抗体およびその使用 | |
| JP7360440B2 (ja) | Pd-l1及びcd137に結合する抗体分子 | |
| CN110392695B (zh) | 针对cd127的抗体和多肽 | |
| TWI839365B (zh) | 間皮素及cd137結合分子 | |
| CN111727197A (zh) | 抗pd-1抗体和治疗方法 | |
| WO2021222544A1 (en) | Ilt-binding agents and methods of use thereof | |
| KR20220016945A (ko) | 다중특이적 단백질 | |
| WO2018027025A1 (en) | Cd40-binding agents and uses thereof | |
| AU2016267577A1 (en) | TIGIT-binding agents and uses thereof | |
| WO2017167672A1 (en) | Trimeric costimulatory tnf family ligand-containing antigen binding molecules | |
| AU2016215394A1 (en) | TNFRSF-binding agents and uses thereof | |
| WO2019032945A1 (en) | CD40 BINDING AGENT AND USES THEREOF | |
| WO2023235703A1 (en) | Therapeutic methods using ilt-binding agents | |
| KR20250143880A (ko) | 항-bcma 항체 또는 그의 항원-결합 단편, 및 그를 포함하는 키메라 항원 수용체 | |
| WO2024251742A1 (en) | Recombinant cd2 binding proteins and their use | |
| RU2826084C2 (ru) | МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137 | |
| HK1245288B (en) | Car t-cells recognizing cancer-specific il 13r-alpha2 | |
| HK40037194B (en) | Anti-pd-1 antibodies and methods of treatment |